Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-06 5:06 pm Sale |
2024-09-30 | 13G | Swiftmerge Acquisition Corp. IVCP |
FARALLON CAPITAL PARTNERS LP | 471,366 9.900% |
-53,634 (-10.22%) |
Filing History |
| 2024-10-16 4:35 pm Purchase |
2024-10-09 | 13D | Squarespace, Inc. SQSP |
FARALLON CAPITAL PARTNERS LP | 5,600,000 6.100% |
5,600,000 (New Position) |
Filing History |
| 2024-05-17 4:58 pm Purchase |
2024-05-09 | 13G | NanoString Technologies, Inc. NSTGQ |
FARALLON CAPITAL PARTNERS LP | 4,391,941 9.100% |
4,391,941 (New Position) |
Filing History |
| 2024-05-08 4:11 pm Purchase |
2024-05-06 | 13D | Exelixis, Inc. EXEL |
FARALLON CAPITAL PARTNERS LP | 26,769,500 9.200% |
909,500 (+3.52%) |
Filing History |
| 2024-02-14 09:33 am Purchase |
2023-12-31 | 13G | Forte Biosciences, Inc. FBRX |
FARALLON CAPITAL PARTNERS LP | 151,740 9.900% |
234 (+0.15%) |
Filing History |
| 2024-02-12 5:11 pm Sale |
2023-12-31 | 13G | Revolution Medicines, Inc. RVMD |
FARALLON CAPITAL PARTNERS LP | 6,750,204 4.100% |
-12,276 (-0.18%) |
Filing History |
| 2024-02-12 3:38 pm Sale |
2023-12-31 | 13G | Beam Therapeutics Inc. BEAM |
FARALLON CAPITAL PARTNERS LP | 4,105,753 5.000% |
-7,716 (-0.19%) |
Filing History |
| 2024-02-08 11:39 am Purchase |
2023-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
FARALLON CAPITAL PARTNERS LP | 4,167,602 7.500% |
206,000 (+5.20%) |
Filing History |
| 2024-02-06 10:16 am Purchase |
2023-12-31 | 13G | Aramark ARMK |
FARALLON CAPITAL PARTNERS LP | 16,899,254 6.400% |
1,518,185 (+9.87%) |
Filing History |
| 2024-02-05 5:28 pm Unchanged |
2024-02-01 | 13D | Cazoo Group Ltd CZOOF |
FARALLON CAPITAL PARTNERS LP | 7,142 14.600% |
0 (Unchanged) |
Filing History |
| 2024-02-05 11:22 am Sale |
2023-12-31 | 13G | Swiftmerge Acquisition Corp. IVCP |
FARALLON CAPITAL PARTNERS LP | 525,000 9.000% |
-1,680,000 (-76.19%) |
Filing History |
| 2024-02-02 09:19 am Purchase |
2023-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX |
FARALLON CAPITAL PARTNERS LP | 5,765,109 9.990% |
710,007 (+14.05%) |
Filing History |
| 2024-02-01 3:50 pm Purchase |
2023-12-31 | 13G | Savara Inc. SVRA |
FARALLON CAPITAL PARTNERS LP | 14,326,911 9.990% |
14,326,911 (New Position) |
Filing History |
| 2024-01-30 1:38 pm Sale |
2023-12-31 | 13G | Berenson Acquisition Corp. I BACA |
FARALLON CAPITAL PARTNERS LP | 413,113 9.900% |
-2,249,387 (-84.48%) |
Filing History |
| 2024-01-30 11:23 am Purchase |
2023-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
FARALLON CAPITAL PARTNERS LP | 2,205,990 9.990% |
788,073 (+55.58%) |
Filing History |
| 2024-01-26 09:11 am Purchase |
2023-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA |
FARALLON CAPITAL PARTNERS LP | 2,025,000 9.600% |
475,000 (+30.65%) |
Filing History |
| 2024-01-25 08:28 am Sale |
2023-12-31 | 13G | Forest Road Acquisition Corp. II FRXB |
FARALLON CAPITAL PARTNERS LP | 0 0.000% |
-400,000 (Position Closed) |
Filing History |
| 2024-01-24 10:07 am Sale |
2023-12-31 | 13G | AVROBIO, Inc. AVRO |
FARALLON CAPITAL PARTNERS LP | 0 0.000% |
-259,667 (Position Closed) |
Filing History |
| 2024-01-22 09:02 am Purchase |
2024-01-12 | 13G | Elevation Oncology, Inc. ELEV |
FARALLON CAPITAL PARTNERS LP | 3,100,000 7.300% |
3,100,000 (New Position) |
Filing History |
| 2024-01-19 09:05 am Sale |
2023-12-31 | 13G | Disruptive Acquisition Corporation I DISA |
FARALLON CAPITAL PARTNERS LP | 0 0.000% |
-1,400,000 (Position Closed) |
Filing History |